Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.

QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

ITGR beats Q2 earnings and revenue estimates, but sales and margins decrease as product headwinds persist ahead of its $5.7B KKR deal.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.